Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols

William L. Hoye, Erik M. Mogalian, Paul B Myrdal

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose. The effects of extreme temperatures on drug delivery of two albuterol sulfate hydrofluoroalkane, metered-dose inhalers (MDIs) were evaluated. Methods. Three Proventil HFA and three Ventolin HFA MDIs were stored at room temperature and served as controls while three of each product were placed in the trunk of a vehicle in Tucson, Arizona. The temperature in the vehicle was monitored for six months. Product performance for each of the MDIs was evaluated at room temperature. An additional study was performed to investigate the performance of the two products when actuated at 4, 22, 47, and 60 °C. Results. The products subjected to extreme environmental temperatures had a modest increase in propellant-leak rate, but the emitted-particle size, dose per actuation, respirable mass, and nonrespirable mass were unaffected. The inhalers tested at temperatures outside the recommended storage conditions exhibited a decrease in particle size, dose per actuation, shot weight and nonrespirable mass as temperature increased. Conversely, increased temperature caused an increase in respirable mass. Conclusion. Despite exposure to extreme temperatures exceeding the manufacturers' recommended storage conditions, drug delivery from Proventil HFA and Ventolin HFA MDIs was not significantly altered. However, drug delivery did change appreciably when the inhalers were tested at different temperatures outside recommended storage conditions.

Original languageEnglish (US)
Pages (from-to)2271-2277
Number of pages7
JournalAmerican Journal of Health-System Pharmacy
Volume62
Issue number21
DOIs
StatePublished - Nov 1 2005

Fingerprint

HFA 134a
Albuterol
Aerosols
Inhalation
Temperature
Metered Dose Inhalers
Pharmaceutical Preparations
Nebulizers and Vaporizers
Particle Size
Drug Storage

Keywords

  • Aerosols
  • Albuterol sulfate
  • Dosage
  • Hydrofluoroalkanes
  • Inhalers
  • Particle size
  • Propellants
  • Stability
  • Storage
  • Sympathomimetic agents
  • Temperature

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Leadership and Management

Cite this

Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols. / Hoye, William L.; Mogalian, Erik M.; Myrdal, Paul B.

In: American Journal of Health-System Pharmacy, Vol. 62, No. 21, 01.11.2005, p. 2271-2277.

Research output: Contribution to journalArticle

@article{67a80d7338c04876b523dda5f148df58,
title = "Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols",
abstract = "Purpose. The effects of extreme temperatures on drug delivery of two albuterol sulfate hydrofluoroalkane, metered-dose inhalers (MDIs) were evaluated. Methods. Three Proventil HFA and three Ventolin HFA MDIs were stored at room temperature and served as controls while three of each product were placed in the trunk of a vehicle in Tucson, Arizona. The temperature in the vehicle was monitored for six months. Product performance for each of the MDIs was evaluated at room temperature. An additional study was performed to investigate the performance of the two products when actuated at 4, 22, 47, and 60 °C. Results. The products subjected to extreme environmental temperatures had a modest increase in propellant-leak rate, but the emitted-particle size, dose per actuation, respirable mass, and nonrespirable mass were unaffected. The inhalers tested at temperatures outside the recommended storage conditions exhibited a decrease in particle size, dose per actuation, shot weight and nonrespirable mass as temperature increased. Conversely, increased temperature caused an increase in respirable mass. Conclusion. Despite exposure to extreme temperatures exceeding the manufacturers' recommended storage conditions, drug delivery from Proventil HFA and Ventolin HFA MDIs was not significantly altered. However, drug delivery did change appreciably when the inhalers were tested at different temperatures outside recommended storage conditions.",
keywords = "Aerosols, Albuterol sulfate, Dosage, Hydrofluoroalkanes, Inhalers, Particle size, Propellants, Stability, Storage, Sympathomimetic agents, Temperature",
author = "Hoye, {William L.} and Mogalian, {Erik M.} and Myrdal, {Paul B}",
year = "2005",
month = "11",
day = "1",
doi = "10.2146/ajhp050067",
language = "English (US)",
volume = "62",
pages = "2271--2277",
journal = "American Journal of Health-System Pharmacy",
issn = "1079-2082",
publisher = "American Society of Health-Systems Pharmacy",
number = "21",

}

TY - JOUR

T1 - Effects of extreme temperatures on drug delivery of albuterol sulfate hydrofluoroalkane inhalation aerosols

AU - Hoye, William L.

AU - Mogalian, Erik M.

AU - Myrdal, Paul B

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Purpose. The effects of extreme temperatures on drug delivery of two albuterol sulfate hydrofluoroalkane, metered-dose inhalers (MDIs) were evaluated. Methods. Three Proventil HFA and three Ventolin HFA MDIs were stored at room temperature and served as controls while three of each product were placed in the trunk of a vehicle in Tucson, Arizona. The temperature in the vehicle was monitored for six months. Product performance for each of the MDIs was evaluated at room temperature. An additional study was performed to investigate the performance of the two products when actuated at 4, 22, 47, and 60 °C. Results. The products subjected to extreme environmental temperatures had a modest increase in propellant-leak rate, but the emitted-particle size, dose per actuation, respirable mass, and nonrespirable mass were unaffected. The inhalers tested at temperatures outside the recommended storage conditions exhibited a decrease in particle size, dose per actuation, shot weight and nonrespirable mass as temperature increased. Conversely, increased temperature caused an increase in respirable mass. Conclusion. Despite exposure to extreme temperatures exceeding the manufacturers' recommended storage conditions, drug delivery from Proventil HFA and Ventolin HFA MDIs was not significantly altered. However, drug delivery did change appreciably when the inhalers were tested at different temperatures outside recommended storage conditions.

AB - Purpose. The effects of extreme temperatures on drug delivery of two albuterol sulfate hydrofluoroalkane, metered-dose inhalers (MDIs) were evaluated. Methods. Three Proventil HFA and three Ventolin HFA MDIs were stored at room temperature and served as controls while three of each product were placed in the trunk of a vehicle in Tucson, Arizona. The temperature in the vehicle was monitored for six months. Product performance for each of the MDIs was evaluated at room temperature. An additional study was performed to investigate the performance of the two products when actuated at 4, 22, 47, and 60 °C. Results. The products subjected to extreme environmental temperatures had a modest increase in propellant-leak rate, but the emitted-particle size, dose per actuation, respirable mass, and nonrespirable mass were unaffected. The inhalers tested at temperatures outside the recommended storage conditions exhibited a decrease in particle size, dose per actuation, shot weight and nonrespirable mass as temperature increased. Conversely, increased temperature caused an increase in respirable mass. Conclusion. Despite exposure to extreme temperatures exceeding the manufacturers' recommended storage conditions, drug delivery from Proventil HFA and Ventolin HFA MDIs was not significantly altered. However, drug delivery did change appreciably when the inhalers were tested at different temperatures outside recommended storage conditions.

KW - Aerosols

KW - Albuterol sulfate

KW - Dosage

KW - Hydrofluoroalkanes

KW - Inhalers

KW - Particle size

KW - Propellants

KW - Stability

KW - Storage

KW - Sympathomimetic agents

KW - Temperature

UR - http://www.scopus.com/inward/record.url?scp=27644472297&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27644472297&partnerID=8YFLogxK

U2 - 10.2146/ajhp050067

DO - 10.2146/ajhp050067

M3 - Article

C2 - 16239418

AN - SCOPUS:27644472297

VL - 62

SP - 2271

EP - 2277

JO - American Journal of Health-System Pharmacy

JF - American Journal of Health-System Pharmacy

SN - 1079-2082

IS - 21

ER -